<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02773797</url>
  </required_header>
  <id_info>
    <org_study_id>Nystrom02</org_study_id>
    <nct_id>NCT02773797</nct_id>
  </id_info>
  <brief_title>Placebo Controlled Evaluation of Sedation and Physiological Response to Intranasal Dexmedetomidine in Severe COPD</brief_title>
  <official_title>Sedation and Physiologic Response to Intranasal Dexmedetomidine in Severe Chronic Obstructive Pulmonary Disease (COPD): A Randomized, Blinded, Placebo Controlled Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dayton VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dayton VA Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A variety of medications have been used to treat the anxiety, discomfort, and fear associated&#xD;
      with continuous and sudden episodic breathlessness in patients with advanced respiratory&#xD;
      disease. Opioids and benzodiazepines, used alone or in combination, are commonly prescribed&#xD;
      for this distressing symptom. Clinicians are concerned about the adverse effects of opioids,&#xD;
      especially respiratory depression, so they frequently prescribe benzodiazepines. Recent&#xD;
      studies have shown that benzodiazepine use is associated with adverse respiratory outcomes in&#xD;
      older adults with Chronic Obstructive Pulmonary Disease (COPD). Dexmedetomidine may be an&#xD;
      alternative to current drug therapies for breathlessness. Dexmedetomidine produces a dose&#xD;
      dependent sedation, anxiolysis, and analgesia without respiratory depression or cognitive&#xD;
      dysfunction.&#xD;
&#xD;
      The drug can be administered intranasally (IN-DEX) to induce light to moderate sedation of&#xD;
      several hours duration.&#xD;
&#xD;
      The objective of the research is to assess the dose dependent safety and efficacy of&#xD;
      intranasal dexmedetomidine compared to intranasal saline (placebo) in clinically stable&#xD;
      patients with severe COPD. This will be accomplished in a staffed acute care setting with&#xD;
      routine vital signs monitoring and continuous pulse oximetry. Patients will be assessed&#xD;
      objectively and subjectively for their level of sedation by validated sedation scales.&#xD;
&#xD;
      The study is an extension of a similarly designed pilot study which did not include a placebo&#xD;
      comparison. Results of the study will be helpful to design additional trials with intranasal&#xD;
      dexmedetomidine in acutely symptomatic COPD patients, exertional dyspnea and exercise&#xD;
      performance, and dyspnea treatment comparisons.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Observer's Assessment of Alertness/Sedation Scale</measure>
    <time_frame>every 15 minutes up to 5 hours after intranasal dexmedetomidine</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sedation Visual Analog Scale (VAS)</measure>
    <time_frame>Every 15 minutes up to 5 hours after intranasal dexmedetomidine</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Vital Signs</measure>
    <time_frame>Every 5 minutes for 90 minutes, then every 15 minutes for up to 5 hours</time_frame>
    <description>heart rate, noninvasive blood pressure, respiratory rate, continuous pulse oximetry</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>IN-DEX 1.0 mcg/kg, intranasal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label &quot;Intranasal-Dexmedetomidine (IN-DEX) intranasal 1.0 mcg/kg&quot; will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IN-DEX, 1.5 mcg/kg intranasal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label &quot;IN-DEX intranasal 1.5 mcg/kg&quot; will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label &quot;Placebo - Saline&quot; will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-DEX 1.0 mcg/kg, intranasal saline</intervention_name>
    <arm_group_label>IN-DEX 1.0 mcg/kg, intranasal saline</arm_group_label>
    <other_name>precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-DEX 1.5 mcg/kg, intranasal saline</intervention_name>
    <arm_group_label>IN-DEX, 1.5 mcg/kg intranasal saline</arm_group_label>
    <other_name>precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Saline</intervention_name>
    <arm_group_label>Placebo - Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe COPD (FEV1 &lt; 50% predicted)&#xD;
&#xD;
          -  Age 45-70&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) Class 3&#xD;
&#xD;
          -  Body Mass Index &lt; 35 kg/meter squared&#xD;
&#xD;
          -  No prior history of adverse reactions to alpha 2 agonists (dexmedetomidine, clonidine)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known adverse reaction, allergy or hypersensitivity, to alpha 2 agonists&#xD;
&#xD;
          -  Not nothing by mouth (NPO)&#xD;
&#xD;
          -  ASA class &gt;3&#xD;
&#xD;
          -  Home oxygen therapy &gt;2LPM by nasal cannula continuous use&#xD;
&#xD;
          -  Any evidence of nasal mucosal inflammation, irritation, bleeding or ulceration&#xD;
&#xD;
          -  Pregnancy, or possibility of pregnancy&#xD;
&#xD;
          -  Coronary heart disease with stable or unstable angina&#xD;
&#xD;
          -  Baseline heart rate &lt;55 beats per minute&#xD;
&#xD;
          -  Bradyarrhythmia, heart block, presence of pacemaker&#xD;
&#xD;
          -  Congestive Heart Failure or known Cardiomyopathy (Ejection Fraction &lt;40% by ECHO,&#xD;
             MUGA, or myocardial perfusion imaging)&#xD;
&#xD;
          -  Cor pulmonale&#xD;
&#xD;
          -  Liver disease (hepatic transaminases &gt; 2x upper limit of normal, cirrhosis, end stage&#xD;
             liver disease)&#xD;
&#xD;
          -  diagnosis of moderate to severe Obstructive Sleep Apnea&#xD;
&#xD;
          -  currently enrolled in any other research study involving drugs or devices&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dayton VA Medical Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2016</study_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>Dexmedetomidine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

